




TASHKENT MEDICAL ACADEMY

100 TMA
ANNIVERSARY



Journal of Educational and Scientific Medicine



Issue 1 (1) | 2023



OAK.uz
Google Scholar

Supreme Attestation Commission of the Cabinet
Ministers of the Republic of Uzbekistan

ISSN: 2181-3175

A New Approach to the Treatment of Anovulatory Infertility in Reproductive-Age Women

[E.O. Gafurxonova¹](#), [Sh.O. Sharipova¹](#), [S.B. Burxonova¹](#), [Z.F. Solieva¹](#)

ABSTRACT

Background. Among the various causes of female infertility, follicle dysfunction accounts for 27%. The aim of the study is to assess the effectiveness of the preservative drug clomiphene citrate in stimulating ovulation in women of different reproductive ages who have anovulatory infertility.

Materials. The study included women of different reproductive ages with 70 cases of anovulatory infertility, of which the I group consisted of 30 women of early reproductive age and the II group included 20 women of late reproductive age. Women who were of reproductive age but refused to induce ovulation at age 20 made up the control group. All women were advised to take a drug containing clomiphene citrate in order to stimulate ovulation. When diagnosing the process of anovulation in the ovaries in all women, hormonal and ultrasound examinations were carried out.

Results. Ovulation has been achieved in 23 (76.7%) women in Group I. In 2 (8.6%) of them, the dose of the ovulatory clomiphene citrate preservative drug is 100 mg. It happened when I increased to 5 (21.7%) while on 150 mg. Pregnancy occurred in 20 (87.0%) of these women. In Group II, ovulation has been achieved in 13 (65.0%) women. In three (23.9%) of them, the dose of the ovulatory clomiphene citrate preservative drug is 100 mg. It occurred when a dose of 150 mg was increased to 2 (15.3%). Pregnancy occurred in 11 (55.0%) of the women in this group.

Conclusion. There is ovulatory infertility the use of the preservative drug clomiphene citrate in stimulating ovulation in women of different reproductive ages has proven its effectiveness by causing ovulation to occur in groups of 76.7% and 65.0%, respectively, and causing pregnancy in groups of 87.0% and 55.0% of women, respectively.

Key words: Anovulatory infertility, reproductive age, ovulation stimulation, Durinum®

INTRODUCTION

Anovulatory infertility is thought to be the most common type of gynecological disease in women of reproductive age [1–12].

Anovulation happens when the processes of choosing, growing, and maturing the dominant follicle are messed up. It is characterized by the stagnation of many small follicles, where androgens are produced at a higher rate than sex steroids [13–18].

In addition to being interested in infertility caused by problems with ovulation, scientists have been putting a lot of effort into finding ways to help these patients, who have been the least studied in clinical practice over the past 10 years [19–25].

However, there is still no solution to the contentious issue of non-ovulation-related infertility. There isn't much information about this problem in foreign

¹ Master of the 2nd year of the Department of Obstetrics and Gynecology of the Tashkent Medical Academy, Tashkent, Uzbekistan

literature, so it's up to us to do research based on a new way to solve it [25–28].

There are no studies on how well the drug clomiphene citrate, which is used as a preservative, works to make ovulation happen in women with anovulatory infertility [28–36].

Anovulatory infertility, especially with clomiphene citrate, can happen to women of different ages who can have children. There is still no clear answer to the question of how much the preservative drug affects the process of folliculogenesis. This again shows how important this study is.

The goal of the study is to see how well the drug clomiphene citrate, which is used as a preservative, works to make ovulation happen in anovulatory infertile women of different ages.

MATERIAL AND METHODS

In the study, there were 70 cases of anovulatory infertility in women of different ages. There were 30 women of early reproductive age in Group I and 20 women of late reproductive age in Group II. The control group was made up of women of reproductive age who didn't want to do anything to make them ovulate at age 20. To make ovulation happen, all women were told to take a drug with clomiphene citrate in it. All women underwent hormonal and ultrasound examinations to determine if there was no ovulation in the ovaries. To perform ultrasound of the pelvic organs, Samsung (Korea) was carried out using transabdominal and transvaginal sensors with a frequency of 3.5–4.5 and 6-7 MGs, respectively, on an ultrasound machine. In this study, we used the drug clomiphene citrate for the first time to stimulate ovulation. The Student t-test was used to look at the study's results from a statistical point of view.

RESULTS

In women of all reproductive ages, ovulation stimulation was carried out using the preservative drug clomiphene citrate according to the following scheme: in women of early reproductive age who are part of the group I, ovulation stimulation was recommended to take 1 tablet at a time for 5 days (50 mg) in the first month, on the 3rd–7th day of the menstrual cycle. It was prescribed to take for 3 to 7 days in the second month of the menstrual cycle, 1 tablet 2 times for 5 days (100 mg), and 1 tablet 3 times (150 mg) for 5 days in the third month of the menstrual cycle.

In women of late reproductive age who are part of Group II, stimulation of ovulation was recommended in

the first month, on the 2nd–6th day of the menstrual cycle, to take 1 tablet at a time for 5 days (50 mg). In the second month of the menstrual cycle, it was prescribed to take for 3 to 7 days, stimulation of ovulation from 1 tablet twice for 5 days (100 mg), and in the third month of the menstrual cycle, for 1 tablet three times (150 mg) for 5 days.

Folliculometry with ultrasound was used to measure the thickness of the endometrium in order to figure out how the menstrual cycle works and how well ovulation works. On ultrasound, the thickness and exogenicity of the endometrium were measured by the number and size of the leading follicles on the 8th, 12th, and 14th days of the menstrual cycle, as well as the formation of a yellow body in the second half of menstruation.

In Group I, the drug clomiphene citrate was used to stimulate ovulation. This led to a significant increase in the maximum follicle diameter ($p < 0.05$) and an average of 2.2 sm.ni in Group II, which is 2.0 sm.ni organized. According to an organized study, the thickness of the endometrium increased significantly ($p < 0.05$) in both of these groups, averaging 0.9 cm in Group I and 1.0 cm in Group II. At the same time, a comparison of two groups on these indicators showed that in patients in Group I, the maximum follicle diameter and the thickness of the endometrium significantly exceeded the corresponding indicators in Group II ($p < 0.05$).

Ovulation has been achieved in 23 (76.7%) women in Group I. In 2 (8.6%) of them, the dose of the ovulatory clomiphene citrate preservative drug is 100 mg. It happened when I increased to 5 (21.7%) while on 150 mg. Pregnancy occurred in 20 (87.0%) of these women. In Group II, ovulation has been achieved in 13 (65.0%) women. In three (23.9%) of them, the dose of the ovulatory clomiphene citrate preservative drug is 100 mg. It occurred when a dose of 150 mg was increased to 2 (15.3%). Pregnancy occurred in 11 (55.0%) of the women in this group.

In women in the comparison group, pregnancy occurred in 3 (15.0%) people (see Figure 1).

So, getting ovulation to happen with the help of the drug clomiphene citrate, which is used as a preservative, is a good way to do it, as it works for 70.1% of women of early and late reproductive age. Even though clomiphene citrate was used to make ovulation happen, there were no serious side effects that made it necessary to stop taking the drug too soon.

Based on the data that was collected, clomiphene citrate has a diameter of 18 mm in the middle of the menstrual cycle after 60 ovulation cycles when a drug

used as a preservative is used. The average number of extra follicles is 44 (70.1%), and all of them are made, and folliculogenesis is stimulated. Two follicles mature every six menstrual cycles.




Figure 1. Ovulation and pregnancy prolapse when using the drug clomiphene citrate in women included in the study, %

The period for the preovulatory phase of follicle development was on average 13.5 days. On the 12th or 14th day of the menstrual cycle, the average diameter of the dominant follicle in women who have had ovulation confirmed is 18.0 mm. A comparison of the size of the dominant follicle in women who belong to both main groups when taking different doses of the clomiphene citrate preservative drug can be seen in this table (see Table 1).

Table 1. The size of the follicles in women included in the study.

KS preservative drug dosage, mg	I-Group, n=30			Group II, n = 20		
	8th day of the MS	12th day of the MS	14th day of the MS	8th day of the MS	12th day of the MS	14th day of the MS
50	9,1±0,2	16,0±0,2	19,1±1,2	9,0±0,1	16,0±0,2	19,0±1,2
100	9,0±0,1	15,8±0,1	19,0±1,3	8,8±0,3	15,8±0,3	18,8±1,4
150	8,9±0,3	15,0±0,3	18,9±1,2	8,7±0,4	15,6±0,1	18,7±1,21
P	>0,05	>0,05	>0,05	>0,05	>0,05	>0,05

Ovulation was achieved in 36 (72.0%) of the total women included in the study. Despite three months of stimulation with the preservative drug clomiphene citrate, anovulatory status was maintained in seven (35.0%) women of late reproductive age. Pregnancy occurred in 33 (66.0%) of the women included in the study. When using Clomiphene citrate preservative drug, an analysis of the occurrence of ovulation and the frequency of pregnancy, depending on the dosage of the

clomiphene citrate preservative drug used, i.e., the dose of the drug per day of 100 mg An increase in the dose of the drug leads to a doubling of the frequency of pregnancy (p<0.05).

Thus, the use of clomiphene citrate preservative in order to stimulate ovulation was achieved for 33 (66.0%) of women included in the study to become pregnant, and in these groups were 23 (76.7%) people and 13 (65.0%), respectively.

DISCUSSION

Anovulatory infertility is one of the most common forms of female infertility. Based on a differentiated approach to the treatment of anovulatory infertility in women, it is necessary to carry them out taking into account their age [3–7].

When treating infertility, clomiphene citrate-based drugs that stop ovulation may be given to help stimulate ovulation. Depending on the patient's specific needs [12–18], the doctor in charge of this drug should choose a treatment that is both easy and effective.

When trying to get a woman of reproductive age to ovulate, it is important to first think about how old she is and how long her menstrual cycle is.

If ovulation doesn't happen during three menstrual cycles, a laparoscopic surgery procedure may be used to stimulate the ovaries. These methods help stimulate ovulation and increase pregnancy rates in women.

Finally, it may be recommended to get pregnant using in vitro fertilization if the location-dependent surgery method does not help either.

In general, anovulatory procedures on women of reproductive age should be done based on a differentiated approach to treating infertility, taking into account the individual characteristics of each patient and the latest scientific and clinical data from the attending doctor.

CONCLUSION

There is ovulatory infertility the use of the preservative drug clomiphene citrate in stimulating ovulation in women of different reproductive ages has proven its effectiveness by causing ovulation to occur in groups of 76.7% and 65.0%, respectively, and causing pregnancy in groups of 87.0% and 55.0% of women, respectively.

Ethics approval and consent to participate - All patients gave written informed consent to participate in the study.

Consent for publication - The study is valid, and recognition by the organization is not required. The author agrees to open publication

Availability of data and material - Available

Competing interests - No

Financing – No financial support has been provided for this work

Conflict of interests - The authors declare that there is no conflict of interest.

REFERENCES

1. Abashidze, A. A. Struktura besplodiya. O chem ne stoit zabivat // Spravochnik vracha obshey praktik i. -2014 -№ 4. - S. 81-84.

2. Gafurova E.O., Xolboeva S.Sh., Nigmatova G.M., Shukurov F.I. Tuxumdonlar follikulyar kistalarini laparoskopik olib tashlashdan so'ng ad'yuvant terapiya samaradorligini baholash // Jurnal Tibbiyotda yangi kun. 11(49) 2022., S.341-343.

3. Nazarenko T. A. Stimulyasiya funksii yaichnikov// T.A.Nazarenko.-5-e izd., dop. i pererab. - M.: Myedpress-inform, 2015. - 288 s.

4. Shukurov F.I. Endokrinnie rasstroystva u jenshin s besplodiem, obuslovlennim dobrokachestvennimi strukturnimi izmeneniyami yaichnikov//Nazariy va klinik tibbiyot jurnali 2016,- №2.,-s 71-73.

5. Shukurov F.I., Djabbarova Yu.K. Otsenka ovarialnogo rezerva u jenshin s besplodiem, obuslovlennim strukturnimi patologiyami yaichnikov, perenesshix endoxirurgicheskie operatsii//Vestnik Tashkentskoy meditsinskoy akademii.2016-№2-s106-108.

6. Shukurov F.I. Rol laparoskopii v lechenii jenskogo besplodiya, obuslovlennogo dobrokachestvennimi strukturnimi izmeneniyami yaichnikov//Jurnal akusherstva i jenskix bolezney 2016, TOM LXV SPYESVIPUSK - №2-s 75-76.

7. Shukurov F.I. Rezultati intraoperatsionnix tsitomorfologicheskix issledovaniy pri strukturnoy patologii yaichnikov u jenshin s besplodiem//Jurnal Byulleten assotsiatsii vrachey Uzbekistana 2016,-№3.,-s 58-61.

8. Shukurov F.I., Ayupova F.M. Osobennosti endoxirurgicheskogo lecheniya i prognozirovaniya retsidiva va follikulyarnix kist yaichnikov//Jurnal Xirurgiya Uzbekistana, 2016,-№4 (72), S.101-104.

9. Shukurov F.I. Primenenie preparata Distreptaza v kompleksnoy reabilitatsionnoy terapii u jenshin, posle laparoskopicheskogo udaleniya follikulyarnix kist yaichnikov//Jurnal Infektsiya, immunitet i farmakologiya 2016,-№7., «Spetsialnyy vipusk. Chast 1»-s 122-126.

10. Shukurov F.I. Primenenie preparata Midiana v reabilitatsii reproduktivnoy funktsii u jenshin, posle endoxirurgicheskogo lecheniya follikulyarnix kist yaichnikov//Jurnal Infektsiya, immunitet i farmakologiya 2017, №2,S 277-283.

11. Xolboeva S.Sh., Shukurov F.I. Korrektsiya gormonalnoy disfunktsii u jenshin s sindromom polikistoznix yaichnikov posle endoxirurgicheskoy operatsii dekortikatsiya yaichnikov//Jurnal teoreticheskoy i klinicheskoy meditsini, №6, 2021. S.-169-172.

12. Shukurov F.I. Minimally Invasive Surgery In Restoring Reproductive Function Of Female Infertility Caused By Benign Ovarian Structural Changes// American Journal of Medicine and Medical Sciences, Volume 6, Number 6, December 2016 P-182-185.

13. Shukurov F.I., Yuldasheva N.Z., Ayupova F.M. Retrospektivniy analiz reproduktivnoy funktsii u jenshin, perenesshix endoxirurgicheskix operatsii na yaichnikax// Jurnal Novosti dermatovenerologii i reproduktivnogo zdorovya 2017, № 3-4 (I), S.155-157.

14. Shukurov F.I. Immunogistoximicheskaya xarakteristika estrogenovix i progesteronovix retseptorov yaichnikov, pri besplodii, obuslovlennom dobrokachestvennimi strukturnimi izmeneniyami yaichnikov//Jurnal teoreticheskoy i klinicheskoy meditsini.2017, №4, S. 82-85.

15. Nazarova G.D., Shukurov F.I. Sostoyanie ovarialnogo rezerva u jenshin s sindromom polikistoznix yaichnikov do i posle endoxirurgicheskoy operatsii dekortikatsiya yaichnikov//Jurnal teoreticheskoy i klinicheskoy meditsini, №6, 2021. S.-119-120.

16. Shukurov F.I., Ayupova F.M., Djabbarova Yu.K. Korrektsiya gormonalnix narusheniy u jenshin s besplodiem, obuslovlennim dobrokachestvennimi strukturnimi izmeneniyami yaichnikov posle endoxirurgicheskogo lecheniya//Jurnal teoreticheskoy i klinicheskoy meditsini, 2019, №5, S.140-141.

17. Shukurov F.I., Bekmirzaeva F.M. Otsenka effektivnosti ispolzovaniya Inotir® v sochetanii s Belara® pri sindrome polikistoznix yaichnikov//Jurnal teoreticheskoy i klinicheskoy meditsini. 2019, №5, S. 100-102.

18. Shukurov F.I., Yuldasheva N.Z. Otsenka effektivnosti razlichnix vidov laparoskopicheskix vmeshatelstv pri lechenii besplodiya u jenshin obuslovlennim sindromom polikistoznix yaichnikov//Jurnal teoreticheskoy i klinicheskoy meditsini, 2019, №5, S.142-143.

19. Shukurov F.I., Ayupova F.M. The Role of Reproductive Surgery in Diagnostics and Treatment of Combined Pathologies in Women with In fertility

Caused by Benign Structural Changes of Ovaries// American Journal of Medicine and Medical Sciences, Volume 9, Number 6, May–2019. P-210-212.

20. Nazarova G.D., Axmedjanova X.Z., Tursunova X.N., Shukurov F.I. Tuxumdonlar polikistoz sindromi sababli tuxumdonlar kauterizatsiyasi jarroxlik amaliyotini o'tkazgan ayollarda reproduktiv saloxiyatini holati// Jurnal Tibbiyotda yangi kun. 11(49) 2022.,S.434-437.

21. Shukurov F.I. The results of immunohistochemical studies of the endometrial receptors in women with infertility caused by benign ovarian structural changes// 7th International IVI Congress” held in Bilbao (Spain), from May 11th to May 13th 2017.

22. Shukurov F.I. Use of contraceptives in rehabilitation of reproductive function in women with infertility after endochirurgical intervention in ovarians// 13 th Seminar of the European Society of Contraception and Reproductive Health Park Inn by Radisson Pribaltiyskaya Saint Petersburg, Russia. Final programme and book of abstracts .2017-s-22-23.

23. Shukurov F.I. Opit vosstanovleniya menstrualnoy funktsii u jenshin s dobrokachestvennimi strukturnimi izmeneniyami yaichnikov posle endoxirurgicheskogo lecheniya//Sbornik tezisov XII Mejdunarodniy kongress po reproduktivnoy meditsine Moskva/ 2018. S.182-183.

24. Shukurov F.I., Ayupova F.M. Novoe v vosstanovlenii fertilnosti u jenshin posle endoxirurgicheskogo lecheniya sindroma polikistoznix yaichnikov//Materiali nauchno-prakticheskoy konferentsii s mejdunarodnim uchastiem «Innovatsionnie texnologii v meditsine// Samarkand// Biologiya va tibbiyot muammolari, 2018, 4,1 (105) 175-176.

25. Shukurov F.I.,Ayupova F.M. Rol immunogistoximicheskix issledovaniy v diagnostike besplodiya u jenshin s sindromom polikistoznix yaichnikov//Sbornik tezisov XXXI mejdunarodnogo kongressa «Novie texnologii v diagnostike i lechenii ginekologicheskix zabolevaniy» s kursom endoskopii//Moskva.,2018.,-S31-33.

26. Xolboeva S.Sh., Gafurova E.O., Solieva Z.F., Shukurov F.I. Tuxumdonlar polikistoz sindromi sababli jarroxlik amaliyotini otkazgan ayollarda gormonal statusining holati//Jurnal Tibbiyotda yangi kun. 11(49) 2022.,S.482-485.

27. Shukurov F.I., Ayupova F.M. Reabilitatsiya reproduktivnoy funktsii jenshin posle endoxirurgicheskogo lecheniya follikuliyarnix kist yaichnikov//Sbornik tezisov XXXI mejdunarodnogo kongressa «Novie texnologii v diagnostike i lechenii ginekologicheskix zabolevaniy» s kursom endoskopii//Moskva.,2018.,-S153-154.

28. Shukurov F.I., Ayupova F.M. Sindrom polikistoznix yaichnikov: etiopatogeneticheskie aspekti, rannaya diagnostika, sposobi reabilitatsii reproduktivnoy funktsii//Metodicheskie rekomendatsii.Tashkent.,2018., S 48.

29. Shukurov F.I., Ayupova F.M., Nigmatova G.M. Follikuliyarnie kisti yaichnikov: diagnostika, prognozirovaniye, usovershenstvovaniye metodov lecheniya, profilaktika, sposobi reabilitatsii reproduktivnoy funktsii //Metodicheskie rekomendatsii. Tashkent., 2018., S 38.

30.X.Z. Axmedjanova., X.N. Tursunova, F.I. Shukurov. Kech reproduktiv yoshdagi ayollarda tuxumdonlar zaxirasining holati//Jurnal Tibbiyotda yangi kun. 10(48) 2022.,S.52-56.

31. Shukurov F.I., Ayupova F.M. Ispolzovanie Inotira v reabilitatsii reproduktivnoy funktsii u jenshin s besplodiem obuslovlennim sindromom polikistoznix yaichnikov//Sbornik tezisov XIII Mejdunarodniy kongress po reproduktivnoy meditsine Moskva. 2019. S. 392.

32. Shukurov F.I., Bekmirzaeva F.M. Opit vosstanovleniya fertilnosti u patsientok s sindromom polikistoznix yaichnikov posle endoxirurgicheskogo lecheniya//Sbornik tezisov XIII Mejdunarodniy kongress po reproduktivnoy meditsine Moskva/2019 S. 444-445.

33. Shukurov F.I., Ayupova F.M. Rol ultrazvukovogo issledovaniya s tsvetnim doplerovskim kartirovaniem v diagnostike dobrokachestvennix strukturnix izmeneniy yaichnikov//Sbornik tezisov XXXII mejdunarodnogo kongressa «Novie texnologii v diagnostike i lechenii ginekologicheskix zabolevaniy» s kursom endoskopii.Moskva.2019.,-S65-66.

34.Shukurov F.I., Ayupova F.M. Rol ad'yuvantnoy gormonalnoy terapii v vosstanovlenii reproduktivnoy funktsii u jenshin posle endoxirurgicheskogo lecheniya follikuliyarnix kist yaichnikov//Ginekologiya. 2021; 23 (1): S. 68–72.

35. Shukurov F.I. Tuxumdonlar polikistoz sindromi. Monografiya.Toshkent, 2022.84b.

36. Shukurov F.I., Mamajanova D.M., Yuldasheva N.Z., Sattarova K.A. Otsenka effektivnosti primeneniya preparata Belara v ad'yuvantnoy terapii sindroma polikistoznix yaichnikov posle endoxirurgicheskogo lecheniya//Eksperimentalnaya i klinicheskaya farmakologiya.2022.Tom 85.,№8.-S.14-16.

37. Shukurov F.I., Nigmatova G.M. Yordamchi reproductiv texnologiyalar. O'quv qo'llanma.Toshkent.2022.84b.

38. Shukurov F.I., Nigmatova G.M. Akusherlik va ginekologiya. Darslik. Toshkent.2022.327b.

**REPRODUKTIV YOSHDAGI AYOLLARDA
ANOVULYATOR BYEPUSHTLIKNI
DAVOLASHDA YANGICHA YONDASHUV**

**Gafurxonova E.O., Sharipova Sh.O., Burxonova
S.B., Solieva Z.F**

Toshkent Tibbiyot Akademiyasi

АБСТРАКТ

Dolzarbli: anovulyator bepustlik mavjud reproduktiv yoshdagi ayollarda ovulyatsiyasini stimullashda klomifen tsitrat saqllovchi preparat samaradorligini baholash.

Materiallar. Tadqiqotga 70 nafar anovulyator bepustlik mavjud turli reproduktiv yoshdagi ayollar kiritildi, ulardan, I - guruhni 30 nafar erta reproduktiv yoshdagi ayollar, II - guruhga 20 nafar kech reproduktiv yoshdagi ayollar tashkil etdi. Nazorat guruhini - 20 nafar ovulyatsiyani stimullashdan bosh tortgan reproduktiv yoshdagi ayollar tashkil etdi. Barcha ayollarga ovulyatsiyani stimullash maqsadida klomifen tsitrat saqllovchi preparati berildi. Barcha ayollarda tuxumdonlarda anovulyatsiya jarayonini tashxislashda gormonal va ultratovush tekshiruvlari amalga oshirildi.

Natijalar. I-guruhda 23 (76,7%) nafar ayollarda ovulyatsiya sodir bo'lishiga erishildi. Ulardan 2 (8,6%) nafarida ovulyatsiya klomifen sitrat saqllovchi dorining dozasi 100mg.gacha oshirilganda, 5(21,7%) nafarida esa 150mg miqdorda berilganda sodir bo'ldi. Ushbu guruhning 20 (87,0%) nafar ayolida homiladorlik sodir bo'ldi. II- guruhda 13 (65,0%) nafar ayollarda ovulyatsiya sodir bo'lishiga erishildi. Ulardan 3 (23,0%) nafarida ovulyatsiya klomifen sitrat saqllovchi dorining dozasi 100mg.gacha oshirilganda, 2(15,3%) nafarida esa 150mg miqdorda berilganda sodir bo'ldi. Ushbu guruhning 11(55,0%) nafar ayolida homiladorlik sodir bo'ldi.

Xulosa. Anovulyator bepustlik mavjud turli reproduktiv yoshdagi ayollarda ovulyatsiyasini stimullashda klomifen sitrat saqllovchi preparatini qo'llash guruxlarda mos ravishda 76,7% va 65,0%da ovulyatsini sodir bo'lishiga va guruxlarga mos ravishda 87,0% va 55,0% ayollarda homiladorlik bo'lishiga olib keldi.

Kalit so'zlar: anovulyator bepustlik, reproduktiv yosh, ovulyatsiyani stimullash, Duinum®.

**НОВЫЙ ПОДХОД К ЛЕЧЕНИЮ
АНОВУЛЯТОРНОГО БЕСПЛОДИЯ У
ЖЕНЩИН РЕПРОДУКТИВНОГО ВОЗРАСТА**

**Гафурхонова Э.О., Шарипова Ш.О., Бурхонова
С.Б., Солиева З.Ф.**

Ташкентская медицинская академия

АБСТРАКТ

Актуальность. Среди различных причин женского бесплодия дисфункция фолликулов составляет 27%. Цель исследования - оценить эффективность кломифена цитрат содержащего препарата в стимуляции овуляции у женщин разного репродуктивного возраста, страдающих ановуляторным бесплодием.

Материалы. В исследование были включены 70 женщины разного репродуктивного возраста с ановуляторным бесплодием, из них I группу составили 30 женщин раннего репродуктивного возраста, а II группу - 20 женщин позднего репродуктивного возраста. Контрольную группу составили 20 женщины репродуктивного возраста, с аналогичной патологией но отказавшиеся вызывать овуляцию в возрасте 20 лет. Всем женщинам было рекомендовано принимать препарат, содержащий цитрат кломифена, для стимуляции овуляции. При диагностике процесса ановуляции в яичниках у всех женщин были проведены гормональные и ультразвуковые исследования.

Результаты. Овуляция была достигнута у 23 (76,7%) женщин в I-ой группы. У 2 (8,6%) из них овуляция наступила когда доза кломифен цитрат содержащего препарата увеличили до 100 мг. У 5 (21,7%), овуляция произошла когда доза данного препарата увеличили до 150 мг. Беременность наступила у 20 (87,0%) из этих женщин. Во II группе овуляция была достигнута у 13 (65,0%) женщин. У трех (23,9%) из овуляция произошла при увеличении дозы кломифен цитрат содержащего препарата до 100 мг. Это произошло, когда доза 150 мг была увеличена до у 2 (15,3%) овуляция достигнута при увеличении доза препарата до 150мг. Беременность наступила у 11 (55,0%) женщин в этой группе.

Заключение. Применение кломифен цитрат содержащего препарата для стимуляции овуляции у женщин с ановуляторным бесплодием доказало свою эффективность, вызывая овуляцию в группах 76,7% и 65,0% соответственно и вызывая беременность в группах 87,0% и 55,0% женщин соответственно.

Ключевые слова: ановуляторное бесплодие, репродуктивный возраст, стимуляция овуляции, Дуинум®